



## Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

October 30, 2023

PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, will report its third quarter 2023 financial results on Monday, November 6, 2023, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host an investor conference call to discuss the financial results and provide a business update.

### Investor Conference Call

The Company will host an investor conference call on Monday, November 6, 2023 at 8:30 am ET. To access the live conference call, please pre-register at: <https://www.netroadshow.com/events/login?show=15609a11&confId=57029>.

For those unable to listen to the live conference call, a replay will be available for 30-days on the Investors section of the Company's website at [www.krystalbio.com](http://www.krystalbio.com).

### About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company's first commercial product, the first-ever redosable gene therapy, and the only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

### CONTACT:

#### Investors and Media:

Meg Dodge  
Krystal Biotech  
[mdodge@krystalbio.com](mailto:mdodge@krystalbio.com)



Source: Krystal Biotech, Inc.